Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $19.1MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hattersley Gary | CHIEF SCIENTIFIC OFFICER | Aug 19 '26 | Option Exercise | $1.87 | 100,000 | $187,000 | 100,000 | Aug 21 04:49 PM |
| Hattersley Gary | CHIEF SCIENTIFIC OFFICER | Aug 19 '26 | Sale | $7.09 | 100,000 | $709,240 | 0 | Aug 21 04:49 PM |
| Gary Hattersley | Officer | Aug 19 '26 | Proposed Sale | $6.96 | 100,000 | $696,000 | — | Aug 19 04:30 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.